Background: Somatostatin analogues appear to have antiproliferative effects
in breast cancer by inhibiting various hormones. Several small phase 1 and
2 clinical trails have evaluated the efficacy of somatostatin analogues, b
ut the results are varied. The purpose of this study was to use the techniq
ue of meta-analysis to determine the effect of somatostatin analogues on tu
mor response, toxicity, and serum hormone levels in women with metastatic b
reast cancer.
Methods: All published and unpublished trials were reviewed. Mete-analysis
was preformed by best linear unbiased estimate regression with observations
weighted inversely to their variance. Significance was considered at P < .
05.
Results: Fourteen studies (N = 210) were included. Positive tumor response
was reported in 87 patients (41.4%). Mean duration of response was 3.9 mont
hs. Response was beat when somatostatin analogues were given as first-line
therapy (69.5% versus 28.5%, P < .006) and in patients with less than or eq
ual to2 metastases (45.0% versus 5.6%, P = .3). Mild side effects occurred
in 47 of 185 patients (25.4%). Therapy was associated with a decrease in se
rum insulin-like growth factor (IGF-1) and an increase in growth hormone.
Conclusions: In patients with metastatic breast cancer, treatment with soma
tostatin analogues was associated with a tumor response of over 40% with fe
w side effects. Best results were achieved when somatostatin analogues were
given as first-line therapy.